Champlain Investment Partners LLC bought a new position in shares of Becton Dickinson and Co (NYSE:BDX) during the 4th quarter, HoldingsChannel reports. The firm bought 122,094 shares of the medical instruments supplier’s stock, valued at approximately $26,135,000.
A number of other institutional investors have also modified their holdings of BDX. BlackRock Inc. grew its holdings in Becton Dickinson and by 6.0% during the 4th quarter. BlackRock Inc. now owns 18,811,302 shares of the medical instruments supplier’s stock worth $4,026,750,000 after acquiring an additional 1,071,288 shares in the last quarter. Atlantic Trust Group LLC grew its holdings in Becton Dickinson and by 597.3% during the 3rd quarter. Atlantic Trust Group LLC now owns 451,035 shares of the medical instruments supplier’s stock worth $88,381,000 after acquiring an additional 386,349 shares in the last quarter. DSM Capital Partners LLC bought a new position in Becton Dickinson and during the 3rd quarter worth about $75,155,000. Alpine Associates Management Inc. bought a new position in Becton Dickinson and during the 4th quarter worth about $55,594,000. Finally, Nuance Investments LLC bought a new position in Becton Dickinson and during the 4th quarter worth about $40,965,000. Institutional investors own 77.50% of the company’s stock.
A number of research firms have recently weighed in on BDX. Piper Jaffray Companies restated an “overweight” rating and issued a $260.00 price target (up from $223.00) on shares of Becton Dickinson and in a report on Tuesday, February 6th. Zacks Investment Research upgraded shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 price target on the stock in a report on Wednesday, January 3rd. Evercore ISI began coverage on shares of Becton Dickinson and in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $245.00 price target on the stock. Deutsche Bank set a $260.00 price target on shares of Becton Dickinson and and gave the company a “buy” rating in a report on Friday, December 29th. Finally, Argus raised their price target on shares of Becton Dickinson and to $235.00 and gave the company a “buy” rating in a report on Thursday, December 14th. They noted that the move was a valuation call. Four research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Becton Dickinson and presently has a consensus rating of “Buy” and a consensus target price of $237.27.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.41 by $0.07. The firm had revenue of $3.08 billion during the quarter, compared to analyst estimates of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. Becton Dickinson and’s revenue was up 5.4% on a year-over-year basis. During the same period last year, the firm posted $2.33 EPS. research analysts anticipate that Becton Dickinson and Co will post 10.94 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 9th will be given a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 1.33%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s payout ratio is currently 229.01%.
In related news, Director Timothy M. Ring sold 269,661 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $217.82, for a total value of $58,737,559.02. Following the completion of the transaction, the director now directly owns 295,753 shares of the company’s stock, valued at approximately $64,420,918.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP James W. Borzi sold 4,048 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $224.98, for a total transaction of $910,719.04. Following the completion of the transaction, the executive vice president now directly owns 5,334 shares of the company’s stock, valued at $1,200,043.32. The disclosure for this sale can be found here. Insiders sold a total of 273,885 shares of company stock valued at $59,686,694 over the last ninety days. 1.00% of the stock is currently owned by insiders.
Becton Dickinson and Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.